Yahoo
Shanghai - Delayed Quote CNY

Joinn Laboratories(China)Co.,Ltd. (603127.SS)

40.09 -4.38 (-9.85%)
At close: 3:00:01 PM GMT+8
Chart Range Bar
Loading chart for 603127.SS
  • Previous Close 44.47
  • Open 44.14
  • Bid 40.09 x --
  • Ask 40.10 x --
  • Day's Range 40.07 - 44.15
  • 52 Week Range 26.25 - 55.68
  • Volume 38,648,005
  • Avg. Volume 40,000,108
  • Market Cap (intraday) 30.041B
  • Beta (5Y Monthly) 0.85
  • PE Ratio (TTM) 26.20
  • EPS (TTM) 1.53
  • Earnings Date (est.) --
  • Forward Dividend & Yield 0.12 (0.27%)
  • Ex-Dividend Date Jun 30, 2026
  • 1y Target Est 39.08

Joinn Laboratories(China)Co.,Ltd. provides preclinical and non-clinical services in the United States, the People's Republic of China, and internationally. It operates through three segments: Non-Clinical Studies Services; Clinical Trial and Related Services; and Sales of Research Models. The Non-Clinical Studies Services segment offers drug safety assessment, drug metabolism and pharmacokinetics DMPK studies, and pharmacology and efficacy studies. Its Clinical Trial and Related Services segment provide clinical contract research organization services, co-managed phase I clinical research units, and bioanalytical services. The Sales of Research Models segment engages in the design, production, breeding, and sale of research models, including non-human primates and rodents. The company also offers cell-based assay (CBA) services. In addition, it offers drug quality research and testing services for protein drugs, vaccines, gene and cell therapy products, and provides customized solutions for early-stage drug discovery, screening, and mechanism research. Joinn Laboratories(China)Co.,Ltd. was incorporated in 1995 and is headquartered in Beijing, China.

www.joinnlabs.com

2,649

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/3/2026, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

603127.SS
14.86%
SSE Composite Index (000001.SS)
9.09%

1-Year Return

603127.SS
11.14%
SSE Composite Index (000001.SS)
9.26%

3-Year Return

603127.SS
54.87%
SSE Composite Index (000001.SS)
19.05%

5-Year Return

603127.SS
40.56%
SSE Composite Index (000001.SS)
3.13%

Earnings Trends

View More

Earnings Per Share (GAAP)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY25
Revenue 316.39M
Earnings 19.77M
Profit Margin 6.25%

Q4

FY24

Q1

FY25

Q2

FY25

Q3

FY25

0
200M
400M
600M
10.0%
15.0%
20.0%

Analyst Insights

View More

Analyst Price Targets

12.60 Low
39.08 Average
40.09 Current
66.39 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    61.64%

  • Return on Assets (ttm)

    -0.25%

  • Return on Equity (ttm)

    13.27%

  • Revenue (ttm)

    1.86B

  • Net Income Avi to Common (ttm)

    1.15B

  • Diluted EPS (ttm)

    1.53

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    4.3B

  • Total Debt/Equity (mrq)

    0.41%

  • Levered Free Cash Flow (ttm)

    -81.81M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: